Patent intelligence · US
US 6537979
Water-insoluble derivatives of hyaluronic acid crosslinked with a biscarbodiimide
Water-insoluble derivatives of hyaluronic acid crosslinked with a biscarbodiimide
Patent details — US 6537979
- Jurisdiction
- US
- Status
- expired
- Grant date
- Mar 25, 2003
- Expiration
- Mar 20, 2023
- Applicant
- ANIKA THERAPEUTICS, INC.
- Claims
- 12
- CPC classes
- A61K, A61K47/36, A61K47/61, A61K47/6903
Quick answer
US 6537979 (Water-insoluble derivatives of hyaluronic acid crosslinked with a biscarbodiimide) is held by ANIKA THERAPEUTICS, INC.. Status: expired. Granted Mar 25, 2003. Expires Mar 20, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ANIKA THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K47/36, A61K47/61, A61K47/6903, A61K9/0014, A61K9/0019
More from ANIKA THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12415779
Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof
granted -
US 12391642
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12331026
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
granted -
US 12264167
Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors
granted -
US 12171741
2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12077506
Indane derivatives as hypoxia inducible factor-2(α) inhibitors
granted -
US 11939303
Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
granted -
US 11753366
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted
Frequently asked questions
What is US patent 6537979?
US 6537979 (Water-insoluble derivatives of hyaluronic acid crosslinked with a biscarbodiimide) is held by ANIKA THERAPEUTICS, INC.. Status: expired. Granted Mar 25, 2003. Expires Mar 20, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6537979?
ANIKA THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.
When does US 6537979 expire?
Our index shows an expiration date of Mar 20, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.